LLY vs NVO: Eli Lilly and Company vs Novo Nordisk A/S Stock Comparison [2026]

📊 Data as of June 24, 2026 · Refreshed weekly

A head-to-head, data-driven comparison of LLY (Eli Lilly and Company) and NVO (Novo Nordisk A/S) — covering valuation, growth, dividends, risk, and which one fits your portfolio. All metrics pulled from live market data.

If you're choosing between LLY and NVO, the answer depends on what kind of investor you are. Both are watched closely in the Healthcare sector, but they look different on almost every metric that matters: P/E, growth rate, dividend, balance-sheet quality, and volatility.

Below we break down the head-to-head numbers, name a winner on each dimension, and give a clear recommendation by investor type. Want to run this comparison live with charts and 50+ metrics? Use the free interactive LLY vs NVO comparison tool.

Eli Lilly and Company (LLY)

Healthcare · Drug Manufacturers - General · NYSE

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metast…

Novo Nordisk A/S (NVO)

Healthcare · Drug Manufacturers - General · NYSE

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The …

Quick Verdict

Better for Growth

Tie

growth profiles are roughly comparable

Better for Value

Tie

both trade at similar earnings multiples

Better for Income

Tie

neither pays a meaningful dividend

Better for Safety

Tie

risk profiles look similar

How to Read This LLY vs NVO Comparison

Stock comparisons can be misleading if you focus on a single metric. A "cheaper" P/E doesn't automatically make a stock a better buy — slower-growing companies should trade at lower multiples. The right framework is to score each name on four independent dimensions and weight them according to your investing goal.

The Four-Dimension Framework

Growth — How fast is the business expanding? We look at year-over-year revenue and EPS growth. Faster growers earn premium multiples but carry execution risk.
Value — Are you paying a fair price? P/E, P/B, EV/EBITDA, and free cash flow yield tell you what the market is charging per dollar of business performance.
Income — Does the stock pay you to wait? Dividend yield, payout ratio, and dividend history matter for retirees, FIRE investors, and anyone funding ongoing expenses.
Safety — How much can you lose if things go wrong? Low beta, manageable debt-to-equity, and high ROE indicate a more durable business.

No single stock wins on all four. LLY and NVO likely each lead on at least one dimension. The "right" answer is the one that matches your portfolio gap — if you already own a basket of high-growth tech, the cheaper, lower-volatility name probably adds more diversification value than another momentum bet.

Side-by-Side Metrics: LLY vs NVO

Metric	LLY	NVO
Price	$1077.75	$45.76
Market Cap	—	—
P/E Ratio (lower is cheaper)	0.00	0.00
EPS	$0.00	$0.00
Dividend Yield	0.00%	0.00%
Beta (volatility vs market)	0.37	0.35
ROE (higher is better)	0.00%	0.00%
Debt/Equity (lower is safer)	0.00	0.00
Revenue Growth (YoY)	0.00%	0.00%
EPS Growth (YoY)	0.00%	0.00%
52-Week High	$0.00	$0.00
52-Week Low	$0.00	$0.00
Sector	Healthcare	Healthcare

Which Stock Has Better Growth?

LLY grew revenue 0.00% and EPS 0.00% year-over-year. NVO grew revenue 0.00% and EPS 0.00%.

Roughly tied — growth profiles are roughly comparable.

Which Stock Is Cheaper on Valuation?

LLY trades at a P/E of 0.00, while NVO trades at 0.00. ROE for LLY is 0.00% versus 0.00% for NVO.

Roughly tied — both trade at similar earnings multiples.

Which Stock Pays More Income?

LLY yields 0.00%; NVO yields 0.00%.

Roughly tied — neither pays a meaningful dividend.

Which Stock Is the Safer Bet?

LLY has a beta of 0.37 and a debt-to-equity ratio of 0.00. NVO sits at beta 0.35 and D/E 0.00.

Roughly tied — risk profiles look similar.

Where LLY and NVO Sit in Their 52-Week Range

Price action over the last 12 months gives important context. A stock near its 52-week high has momentum on its side but limited room before profit-taking; one near its low may be a value opportunity or a structural problem.

Key Risks for LLY and NVO

Every stock has tail risks that the headline numbers don't capture. Here's what stands out from the available metrics:

LLY: low beta of 0.37 dampens both upside and downside vs. the broader market.
NVO: low beta of 0.35 dampens both upside and downside vs. the broader market.

This is a quick heuristic risk scan, not a full risk assessment. Always read the "Risk Factors" section of each company's most recent 10-K filing before investing.

LLY vs NVO — Best Pick by Investor Type

Long-term holder (10+ years): Lean toward either name works; durability and balance-sheet strength matter more than the next-quarter print.
Income / dividend-focused: either name works — higher yield, but always check payout sustainability before chasing.
Aggressive growth: either name works — faster top-line and EPS expansion at the cost of richer multiples.
Value-oriented: either name works — paying less per dollar of earnings, with the trade-off of slower growth.

The Bottom Line: LLY vs NVO

Neither name dominates — they're a genuine LLY vs NVO toss-up that comes down to which dimension matters most for your portfolio.

If you're the kind of investor who hates picking, the easiest answer is to own both names in equal weight inside a sector basket and rebalance once a year. That way, you capture the winner without having to predict it, and you pay the lowest possible behavioral cost (no second-guessing, no FOMO).

If you must pick one, anchor on the dimension that fixes your biggest portfolio gap — not the one with the most exciting headline. Tilting toward defensive names when you already own three growth winners adds more risk-adjusted return than another momentum bet.

Metrics Glossary — What Each Number Means

If you're new to fundamental analysis, here's a plain-English reference for every metric in the table above:

P/E Ratio (Price-to-Earnings): Share price divided by earnings per share. Tells you how many years of current earnings the stock costs. Lower = cheaper, but slow growers should have lower P/Es.
EPS (Earnings Per Share): Net income divided by shares outstanding. The per-share slice of company profits.
Market Cap: Share price × shares outstanding. The market's total valuation of the company's equity.
Dividend Yield: Annual dividend per share ÷ current price, expressed as a percent. A 3% yield means you receive $3 per year for every $100 invested at today's price.
Beta: Volatility relative to the broader market (S&P 500 = 1.0). Beta of 1.5 means the stock historically moves 1.5× the market, both up and down.
ROE (Return on Equity): Net income ÷ shareholder equity. How efficiently the company turns equity capital into profit. Above 15% is generally considered high quality.
Debt-to-Equity: Total debt ÷ shareholder equity. Lower ratios mean less leverage and lower interest-rate risk.
Revenue Growth (YoY): Percentage change in revenue versus the year-ago period. The single best top-line health check.
EPS Growth (YoY): Same comparison but for earnings per share — captures both revenue growth and operating leverage.
52-Week High / Low: The trailing 12-month price range. Useful for context on current price (e.g. a stock near its 52-week high is in an uptrend; near the low is in a downtrend or value zone).

Run a Live LLY vs NVO Comparison

The numbers above reflect the latest available data, but markets move every minute. For a real-time, interactive head-to-head with price charts (1D to YTD), all 50+ metrics, and AI-powered insights, use our free tool — it's free, no signup required, and shareable:

Compare LLY vs NVO live →

Frequently Asked Questions: Is LLY

Is LLY a better buy than NVO in 2026?

It depends on your investment goal. For growth investors, Both LLY and NVO are roughly comparable on this dimension has the edge — LLY grew revenue 0.00% versus 0.00% for NVO. For value investors, Both LLY and NVO are roughly comparable on this dimension looks more attractive on earnings multiples (P/E 0.00 vs 0.00). For income, Both LLY and NVO are roughly comparable on this dimension pays a higher yield (0.00% vs 0.00%). For safety, Both LLY and NVO are roughly comparable on this dimension has the more defensive profile (beta 0.37 vs 0.35).

What is the P/E ratio of LLY vs NVO?

LLY trades at a price-to-earnings (P/E) ratio of 0.00, while NVO trades at 0.00. A lower P/E means you pay less per dollar of current earnings — NVO is the cheaper name on this metric. However, a higher P/E often reflects faster expected growth, so don't pick on P/E alone.

Does LLY or NVO pay a higher dividend?

LLY currently yields 0.00% and NVO yields 0.00%. NVO pays the higher current yield. Always verify payout ratio and dividend history before treating yield as guaranteed income — a high yield can also be a warning sign of a falling share price.

Which stock is more volatile, LLY or NVO?

LLY has a beta of 0.37 and NVO has a beta of 0.35. A beta above 1.0 means the stock historically moves more than the broader market; below 1.0 means it moves less. LLY has been the more volatile name based on historical price action.

What is the market cap of LLY vs NVO?

LLY has a market capitalization of — and NVO is at —. Market cap is share price multiplied by shares outstanding and reflects the total equity value the market assigns to the company.

Should I buy LLY or NVO for long-term investing?

For a long-term holder (10+ years), the safer-quality name usually wins because compounding requires durability. Both LLY and NVO are roughly comparable on this dimension screens better on safety metrics here: lower beta, more conservative debt levels, and stronger return on equity. That said, NVO is growing faster, so a long-term investor may want both — or split allocation 60/40 toward the safer name.

Which has higher growth, LLY or NVO?

NVO is the faster grower right now. LLY grew revenue 0.00% year-over-year and EPS 0.00%; NVO grew revenue 0.00% and EPS 0.00%. LLY's slower growth often comes with a lower valuation — it's the classic growth-vs-value trade-off.

Is LLY overvalued compared to NVO?

LLY trades at a higher P/E than NVO, which can mean the market is pricing in faster expected growth. Whether that premium is justified depends on whether LLY can actually deliver the implied earnings expansion. Cross-check P/E with PEG ratio (P/E ÷ growth rate) — a PEG under 1.5 is generally considered reasonable, over 2.0 starts to look stretched.

What sector are LLY and NVO in?

LLY (Eli Lilly and Company) operates in the Healthcare sector, specifically the Drug Manufacturers - General industry. NVO (Novo Nordisk A/S) is in the Healthcare sector, specifically the Drug Manufacturers - General industry. Because both are in the same sector, this is a true head-to-head comparison.

How do I decide between LLY and NVO?

Start with your goal. (1) If you need income, weight the higher-yield name. (2) If you want growth, weight the faster top-line and EPS grower. (3) If you want capital preservation, weight the lower-beta, lower-debt, higher-ROE name. (4) If you're unsure, the most common professional approach is to own both in a sector basket so you don't have to predict the winner — and rebalance annually.

Disclaimer: This comparison is generated from live market data for informational purposes only. It is not investment advice, a recommendation to buy or sell any security, or a substitute for the analysis of a licensed financial advisor. Past performance is not indicative of future results. Always read the most recent 10-K and consult a qualified professional before making investment decisions. StockSignal24 is not responsible for losses incurred from trading decisions made based on this content.